The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.
Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma
Open accessAbstract
BACKGROUND: Data are lacking on whether lenalidomide maintenance therapy prolongs the time to disease progression after autologous hematopoietic stem-cell transplantation in patients with multiple myeloma. METHODS: Between April 2005 and July 2009, we randomly assigned 460 patients who were younger than 71 years of age and had stable disease or a marginal, partial, or complete response 100 days after undergoing stem-cell transplantation to lenalidomide or placebo, which was administered until disease progression. The starting dose of lenalidomide was 10 mg per day (range, 5 to 15). RESULTS: The study-drug assignments were unblinded in 2009, when a planned interim analysis showed a significantly longer time to disease progression in the lenalidomide group. At unblinding, 20% of patients who received lenalidomide and 44% of patients who received placebo had progressive disease or had died (P<0.001); of the remaining 128 patients who received placebo and who did not have progressive disease, 86 crossed over to lenalidomide. At a median follow-up of 34 months, 86 of 231 patients who received lenalidomide (37%) and 132 of 229 patients who received placebo (58%) had disease progression or had died. The median time to progression was 46 months in the lenalidomide group and 27 months in the placebo group (P<0.001). A total of 35 patients who received lenalidomide (15%) and 53 patients who received placebo (23%) died (P=0.03). More grade 3 or 4 hematologic adverse events and grade 3 nonhematologic adverse events occurred in patients who received lenalidomide (P<0.001 for both comparisons). Second primary cancers occurred in 18 patients who received lenalidomide (8%) and 6 patients who received placebo (3%). CONCLUSIONS: Lenalidomide maintenance therapy, initiated at day 100 after hematopoietic stem-cell transplantation, was associated with more toxicity and second cancers but a significantly longer time to disease progression and significantly improved overall survival among patients with myeloma. (Funded by the National Cancer Institute; ClinicalTrials.gov number, NCT00114101.).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Lenalidomide is the standard of care for maintenance therapy for most patients.142–147”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [143]
Experimental — accuracy not yet measuredIn the citing paper
“Patients who have disease progression while not on treatment with lenalidomide can often be re-treated effectively with this agent37,38, sometimes multiple times, and typically in combination with proteasome inhibitors such as carfilzomib39 and ixazomib40 or with daratumumab41.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [37]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer series in statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,239
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
Toxicity and response criteria of the Eastern Cooperative Oncology Group
Oken, M. M., Creech, R. H., Tormey, D. C., Horton, J., Davis, T. E., Mcfadden, E. T., & Carbone, P. P. (1982) · American Journal of Clinical Oncology · doi:10.1097/00000421-198212000-00014 · Cited by 11,686
Cox, D. R., & Oakes, D. (2018) · Chapman & Hall/CRC eBooks · doi:10.1201/9781315137438 · Cited by 6,269
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,957
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationPalumbo, A. P., & Anderson, K. C. (2011) · New England Journal of Medicine · doi:10.1056/nejmra1011442 · Cited by 2,382
Self-citationThe Statistical Analysis of Failure Time Data
Klein, J. P., Kalbfleisch, J. D., & Prentice, R. L. (1982) · Technometrics · doi:10.1080/00401706.1982.10487769 · Cited by 2,248
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A. A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2007) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,241
Raje, N. S., & Anderson, K. C. (2000) · Current Treatment Options in Oncology · doi:10.1007/s11864-000-0017-x · Cited by 2,164
Self-citation
Flagged first, then by citations
Research works printed but not linked: 2
- 10.1001/archinte.135.1.147 · DOI
- 10.2307/2281868 · DOI · Paper page
Cited by
Sorted by citations
Items 801–900 of 1,000
Randall, K., Kaparou, M., Xenou, E., Paneesha, S., Kishore, B., Kanellopoulos, A., Lovell, R., Holder, K., Suhr, J., Baker, L., et al. (2017) · European Journal Of Haematology · doi:10.1111/ejh.12917 · Cited by 4
EBV-related lymphoma after long-term daratumumab treatment: a case report
Verpoorte-Botden, I. P. G., Minnema, M. C., & Raymakers, R. A. P. (2020) · Blood Cancer Journal · doi:10.1038/s41408-020-00379-y · Cited by 4
Kunacheewa, C., Feng, L., Manasanch, E. E., Bashir, Q., Patel, K. K., Mehta, R. S., Kaufman, G. P., Srour, S. A., Saini, N., Iyer, S. P., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17393 · Cited by 4
Self-citationLenalidomide for Multiple Myeloma
Bertolini, F. (2012) · New England Journal of Medicine · doi:10.1056/nejmc1206734 · Cited by 4
Maintenance Lenalidomide After Transplantation in Multiple Myeloma Prolongs Survival—In Most
Mikhael, J. R. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.74.7014 · Cited by 4
Ji, Y., Li, H., Zhang, H., Cheng, H., Wang, Y., Xu, K., & Li, Z. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1516471 · Cited by 3
Moreau, P., Hulin, C., Talbot, A., Demarquette, H., Caillot, L., Chalopin, T., Bobin, A., Manier, S., Leleu, X. P., Karlin, L., et al. (2025) · Blood Cancer Journal · doi:10.1038/s41408-025-01387-6 · Cited by 3
Multiple myeloma in 2026 — current guidelines and new therapies
Charliński, G., Vesole, D. H., & Jurczyszyn, A. (2026) · Nowotwory Journal of Oncology · doi:10.5603/njo.108723 · Cited by 3
Wilk, C. M., Heinzler, N., Boquoi, A., Cadeddu, R., Strapatsas, T., Dienst, A., Majidi, F., Deenen, R., Bruns, I., Schroeder, T. A., et al. (2016) · International Journal of Cancer · doi:10.1002/ijc.30257 · Cited by 3
Beksaç, M., Seval, G. C., Koyun, D., Topçuoğlu, P., Yüksel, M. K., Gürman, G., & İlhan, O. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.12.007 · Cited by 3
Thromboprophylaxis in multiple myeloma: a case-based review with practical guidelines
Charalampous, C. M., Shah, D., Kumar, S. K., & Chakraborty, R. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05733-9 · Cited by 3
Colesevelam for lenalidomide associated diarrhea in patients with multiple myeloma
Hultcrantz, M. L., Hassoun, H., Korde, N., Maclachlan, K. H., Mailankody, S., Patel, D., Shah, U. A., Tan, C. R. C., Chung, D. J., Lahoud, O. B., et al. (2024) · Blood Cancer Journal · doi:10.1038/s41408-024-01136-1 · Cited by 3
Self-citationKüçük, C., Akman, B., Hu, X., Hatipoğlu, T., Şeyhanlı, A., Ceylan, A., Yılmaz, B., Öztürk, O. C., Erdağ, T. K., & Özsan, G. H. (2025) · Current Issues in Molecular Biology · doi:10.3390/cimb47040244 · Cited by 3
Current and Future Directions of Immunotherapies in Multiple Myeloma
Biltibo, E. A., Surapaneni, M., Hadidi, S. A., Suvannasankha, A., & Jayani, R. (2025) · American Society of Clinical Oncology Educational Book · doi:10.1200/edbk-25-473316 · Cited by 4
Pomalidomide in the Treatment of Relapsed Multiple Myeloma
Forsberg, P. A., & Mark, T. M. (2013) · Future Oncology · doi:10.2217/fon.13.105 · Cited by 3
Guo, T., Huang, X., Wen, L., & Lu, J. (2017) · Europe PMC (PubMed Central) · doi:10.4103/0366-6999.198017 · Cited by 3
Consenso Mexicano de Mieloma Múltiple
de la Peña-Celaya, J. A., Aguilar-Luévano, J., Alcivar-Cedeño, L. M., Álvarez-Vera, J. L., Anaya-Cuéllar, I., Añorve-Hernández, É., Arana-Luna, L. L., Arteaga-Ortíz, L., Baez-Islas, P. E., Banda-García, L. I., et al. (2020) · Gaceta Médica de México · doi:10.24875/gmm.m20000393 · Cited by 3
Harnessing the T Cell to Treat Multiple Myeloma: Dawn of a New Therapeutic Paradigm
Keller, A. L., Sherbenou, D. W., Forsberg, P. A., & Mark, T. M. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.925818 · Cited by 3
Tsubokura, Y., Yoshimura, H., Satake, A., Nasa, Y., Tsuji, R., Ito, T., & Nomura, S. (2022) · Immunity Inflammation and Disease · doi:10.1002/iid3.688 · Cited by 3
Hu, S.-L., Liu, M., & Zhang, J. (2022) · World Journal of Clinical Cases · doi:10.12998/wjcc.v10.i32.11712 · Cited by 3
Arribas, I., Maluquer, C., Pomares, H., Carro, I., Baca, C., Bosch‐Vilaseca, A., Arévalo, C. E., Montane, C., Ribes‐Amorós, J., Zamora, L., et al. (2023) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2023.2234527 · Cited by 3
Takamatsu, H., Matsuda, T., Mizuno, S., Takahashi, T., Fuchida, S., Hanamura, I., Kataoka, K., Tsukada, N., Matsumoto, M., Hangaishi, A., et al. (2023) · Haematologica · doi:10.3324/haematol.2023.283202 · Cited by 3
Gołoś, A., Mikulski, D., Grobelska-Kowalik, M., Mądry, K., Lis, K., Sobas, M., Ożańska, A., Czemerska, M., Hawrylecka, D., Stelmach-Gołdyś, A., et al. (2024) · Współczesna Onkologia · doi:10.5114/wo.2024.141727 · Cited by 3
Therapy-related myeloid malignancies in patients with multiple myeloma.
Kubicki, T., Adamska, M., Żyłka, K., Dytfeld, D., & Gil, L. (2024) · Acta Haematologica Polonica · doi:10.5603/ahp.101051 · Cited by 3
Perrot, A. (2024) · La Presse Médicale · doi:10.1016/j.lpm.2024.104262 · Cited by 3
Wu, W., Wang, Y., Lou, Y., Fan, X., Yang, W., Tang, F., Zhao, Z., & Dong, H. (2025) · Expert Review of Pharmacoeconomics & Outcomes Research · doi:10.1080/14737167.2025.2461636 · Cited by 3
Glutarimides: Biological activity, general synthetic methods and physicochemical properties
Popović‐Djordjević, J. B., Vitnik, V., Vitnik, Ž., & Ivanović, M. (2014) · Hemijska industrija · doi:10.2298/hemind140701073p · Cited by 3
Mactier, C. E., & Islam, M. S. (2012) · Oncology Reviews · doi:10.4081/oncol.2012.e14 · Cited by 3
Martino, M. V., Recchia, A. G., Console, G., Gentile, M., Cimminiello, M., Gallo, G. A., Ferreri, A., Naso, V., Irrera, G., Messina, G., et al. (2017) · Expert Opinion on Orphan Drugs · doi:10.1080/21678707.2017.1387050 · Cited by 3
Duong, V. H., Holtzman, N. G., Koka, R., Singh, Z. N., Zou, Y. S., Emadi, A., Rapoport, A. P., Kocoglu, M. H., Baer, M. R., & Badros, A. Z. (2019) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2019.1633639 · Cited by 3
Holmberg, L., Green, D., Libby, E. N., & Becker, P. S. (2019) · Acta Haematologica · doi:10.1159/000501298 · Cited by 3
Suichi, T., & Misawa, S. (2020) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12560 · Cited by 3
Lenalidomide‐associated progressive multifocal leukoencephalopathy
Nishimura, K., Iwai, Y., Yabuki, M., Fuse, H., Nakamichi, K., Takahashi, K., Suzuki, T., Saijo, M., Fukushima, T., & Kuwabara, S. (2020) · Clinical and Experimental Neuroimmunology · doi:10.1111/cen3.12606 · Cited by 3
Mexican Consensus of Multiple Myeloma
de la Peña-Celaya, J. A., Aguilar-Luévano, J., Alcivar-Cedeño, L. M., Álvarez-Vera, J. L., Anaya-Cuéllar, I., Añorve-Hernández, É., Arana-Luna, L. L., Arteaga-Ortíz, L., Baez-Islas, P. E., Banda-García, L. I., et al. (2020) · Gaceta Médica de México · doi:10.24875/gmm.m20000392 · Cited by 4
Klinik und Therapie des multiplen Myeloms
Mai, E. K., & Goldschmidt, H. (2014) · Der Radiologe · doi:10.1007/s00117-013-2625-z · Cited by 3
Takamatsu, H., Munemoto, S., Murata, R., Terasaki, Y., Nakajima, K., & Nakao, S. (2013) · PubMed · Cited by 3
Autologous Hematopoietic Stem Cell Transplantation and Maintenance Therapy for Multiple Myeloma
McCarthy, P. L., Owzar, K., & Hahn, T. (2013) · International Journal of Hematologic Oncology · doi:10.2217/ijh.13.2 · Cited by 3
Self-citationPomalidomide in the Treatment of Relapsed and Refractory Multiple Myeloma
Roziaková, Ĺ., Mistrík, M., & Bátorová, A. (2014) · Klinicka onkologie · doi:10.14735/amko2014318 · Cited by 3
Immunomodulatory agents changing the landscape of multiple myeloma treatment
Niesvizky, R. (2013) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2012.12.011 · Cited by 3
Kawamoto, S., Hidaka, Y., Kaneko, Y., Misawa, H., Nagahori, K., Yoshino, A., Okamura, T., Ban, S., Ueda, Y., & Takeda, T. (2019) · CEN Case Reports · doi:10.1007/s13730-019-00382-8 · Cited by 3
Maintenance Strategies After Hematopoietic Cell Transplantation
Culos, K. A. A., Gatwood, K. S., & Byrne, M. T. (2020) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1002/phar.2407 · Cited by 3
Kesireddy, M., & Holstein, S. A. (2022) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2022.2032656 · Cited by 3
Hourigan, C. S., McCarthy, P. L., & Lima, M. J. G. D. (2014) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2014.01.005 · Cited by 3
Self-citationKubicki, T., Dytfeld, D., Wróbel, T., Jamroziak, K., Robak, P. J., Czyż, J., Tyczyńska, A., Druzd‐Sitek, A., Giannopoulos, K., Szczepaniak, T., et al. (2023) · British Journal of Haematology · doi:10.1111/bjh.19097 · Cited by 3
Autologous Hematopoietic Stem Cell Transplantation for Multiple Myeloma
Mangan, P. A., Gleason, C. L., & Miceli, T. S. (2013) · Clinical journal of oncology nursing · doi:10.1188/13.cjon.43-47 · Cited by 3
Wang, X., Vogt, B. E., Shanahan, L., Siddiqui, A. D., Subramonia-Iyer, S., Khanani, S. A., Bednarik, J. L., Mittal, K., Ramanathan, M., Gerber, J. M., et al. (2020) · Blood Cells Molecules and Diseases · doi:10.1016/j.bcmd.2020.102482 · Cited by 3
Shea, L. K., Watkins, M. P., Wan, F., Cashen, A. F., Wagner‐Johnston, N. D., Jacoby, M. A., Abboud, C. N., DiPersio, J. F., Hurd, D. D., Jaglowski, S. M., et al. (2020) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2020.08.017 · Cited by 3
Self-citationJones, J. R., Pawlyn, C., & Jackson, G. H. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1945578 · Cited by 3
Second Primary Malignancies and Myeloma Therapy: Fad or Fact?
Usmani, S. Z. (2012) · Oncotarget · doi:10.18632/oncotarget.661 · Cited by 3
The Evaluation and Counseling of Candidates for Hematopoietic Cell Transplantation
Scott, B. L., & Sandmaier, B. M. (2015) · Wiley eBooks · doi:10.1002/9781118416426.ch29 · Cited by 3
Pardo, A. G. (2012) · Cited by 3
Whiteley, A., Ijioma, S. C., Ray, D., Langerman, S. S., Hu, E., Pierre, A. E., Mark, T. M., & Yimer, H. A. (2025) · Current Oncology · doi:10.3390/curroncol32050268 · Cited by 2
Can I stop my treatment, doctor? Is MRD-guided therapy ready for prime time?
Derman, B. A. (2025) · Hematology · doi:10.1182/hematology.2025000761 · Cited by 2
Dytfeld, D., Wróbel, T., Jamroziak, K., Kubicki, T., Robak, P. J., Pula, A. E., Walter‐Croneck, A., Czyż, J., Tyczyńska, A., Druzd‐Sitek, A., et al. (2026) · The Lancet Haematology · doi:10.1016/s2352-3026(26)00011-6 · Cited by 2
VI. Autologous stem cell transplantation and maintenance therapy
Moreau, P. (2013) · Hematological Oncology · doi:10.1002/hon.2066 · Cited by 2
Lenalidomide and risk of second primary malignancy—is disease context key?
Pawlyn, C., & Bird, S. (2022) · The Lancet Haematology · doi:10.1016/s2352-3026(22)00334-9 · Cited by 2
The first relapse in multiple myeloma: how to pick the next best thing
Devarakonda, S. S., Sharma, N., & Efebera, Y. A. (2022) · Hematology · doi:10.1182/hematology.2022000356 · Cited by 2
Radionuclide Therapy of Leukemias and Multiple Myeloma
Sollini, M., Bartoli, F., Galimberti, S., Boni, R., & Erba, P. A. (2022) · Springer eBooks · doi:10.1007/978-3-031-05494-5_48 · Cited by 2
Xu, T., Yang, Y., Li, J., Xu, J., Wang, W., Wang, Y., Maihemaiti, A., Ren, L., Lan, T., Zhou, C., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05148-y · Cited by 2
Moustafa, M. A., Parrondo, R. D., Abdulazeez, M. F., Roy, V., Sher, T., Alegria, V. R., Warsame, R. M., Fonseca, R., Rasheed, A., Gonsalves, W. I., et al. (2023) · Anti-Cancer Drugs · doi:10.1097/cad.0000000000001520 · Cited by 2
Two Cases of Plasma Cell Dyscrasias With Systemic Involvement of Breast
Morris, G. J., Schmidt, P. H., & Jagannath, S. (2014) · Seminars in Oncology · doi:10.1053/j.seminoncol.2014.06.007 · Cited by 2
Current Treatment Approaches to Multiple Myeloma with New Agents
Maral, S., Albayrak, M., & Pala, Ç. (2018) · Journal of Clinical and Experimental Investigations · doi:10.5799/jcei.433823 · Cited by 2
An Attempt to Quantitate “Value” In Medical Oncologic Therapy
Hancock, C., Green, L., Lestingi, T. M., & Bitran, J. D. (2018) · Cureus · doi:10.7759/cureus.2810 · Cited by 2
Spontaneous remission and clonal evolution in lenalidomide associated secondary AML
Waller, D. D., Monczak, Y., Michel, R. P., Shustik, C., & Sébag, M. (2020) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2020.1725504 · Cited by 2
Evolution of diagnostic workup and treatment for multiple myeloma 2013‐2019
Schjesvold, F. H. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13464 · Cited by 2
Ixazomib and lenalidomide maintenance therapy in multiple myeloma
Parrondo, R. D., Alegria, V. R., Roy, V., Sher, T., Chanan-Khan, A. A., & Ailawadhi, S. (2020) · Annals of Hematology · doi:10.1007/s00277-020-04340-8 · Cited by 2
Cherniawsky, H. M., Kukreti, V., Reece, D. E., Masih‐Khan, E., McCurdy, A. B. R., Jimenez-Zepeda, V. H., Sébag, M., Song, K., White, D. J., Stakiw, J., et al. (2021) · European Journal Of Haematology · doi:10.1111/ejh.13596 · Cited by 2
Treatment of multiple myeloma in 2021
Minařík, J. (2021) · Klinická farmakologie a farmacie · doi:10.36290/far.2021.020 · Cited by 2
IATROGENIC SYSTEMIC LYMPHEDEMA FOLLOWING MULTIPLE MYELOMA TREATMENT
Radu, S., Wilson, J., Bagwell, A. K., Meyers, G., & Nauta, A. (2022) · Lymphology · doi:10.2458/lymph.5403 · Cited by 2
Initial Therapy of Multiple Myeloma (MM)
de la Gándara, J. M. F.-R. (2023) · ANALES RANM · doi:10.32440/ar.2023.140.01.rev08 · Cited by 2
Positron Emission Tomography/Computed Tomography Transformation of Oncology
Murtazaliev, S., Rowe, S. P., Sheikhbahaei, S., Werner, R. A., & Sólnes, L. B. (2024) · PET Clinics · doi:10.1016/j.cpet.2023.12.010 · Cited by 2
Miyao, K., Sakemura, R. L., Sakai, T., Tsushita, N., Kato, T., Niimi, K., Ono, Y., & Sawa, M. (2013) · Annals of Hematology · doi:10.1007/s00277-013-1835-9 · Cited by 2
Nishihori, T., Komrokji, R. S., Shain, K. H., & Anasetti, C. (2014) · Bone Marrow Transplantation · doi:10.1038/bmt.2014.233 · Cited by 2
Second transplant as a standard for multiple myeloma
McCarthy, P. L. (2014) · The Lancet Oncology · doi:10.1016/s1470-2045(14)70279-7 · Cited by 2
Self-citationOptimizing outcomes for patients with newly diagnosed multiple myeloma eligible for transplantation
Moreau, P., & Touzeau, C. (2013) · Leukemia Supplements · doi:10.1038/leusup.2013.4 · Cited by 2
Zago, M., Adam, P., Goldschmidt, H., Fend, F., Kanz, L., & Weisel, K. C. (2013) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2013.07.101 · Cited by 2
Giralt, S., McCarthy, P. L., Anderson, K. C., Carter, S. L., Richardson, P. G. G., Rajkumar, S. V., Laport, G. G., Stadtmauer, E. A., Pasquini, M. C., & Horowitz, M. M. (2013) · Transplantation and Cellular Therapy · doi:10.1016/j.bbmt.2013.03.015 · Cited by 2
Self-citationDesenlaces clínicos en hematoncología: diez años de investigaciones en Pubmed
Rosselli, D., Diaz-Castrillon, C. E., & Gutiérrez, L. (2015) · Revista Colombiana de Cancerología · doi:10.1016/j.rccan.2015.02.002 · Cited by 2
Holmberg, L., Becker, P. S., & Bensinger, W. (2017) · Acta Haematologica · doi:10.1159/000455937 · Cited by 2
Radionuclide Therapy of Leukemias and Multiple Myeloma
Sollini, M., Galimberti, S., Boni, R., & Erba, P. A. (2016) · Springer eBooks · doi:10.1007/978-3-319-26067-9_48-1 · Cited by 2
New Treatment Methods in Multiple Myeloma
Jakab, S., Lázár, E., Benedek, I., Köpeczi, J. B., Pakucs, A., & Benedek, I. (2017) · Journal of Interdisciplinary Medicine · doi:10.1515/jim-2017-0055 · Cited by 2
Lund, J., Gruber, A., Lauri, B., Duru, A. D., Blimark, C. H., Swedin, A., Hansson, M., Forsberg, K., Ahlberg, L., Carlsson, C., et al. (2018) · Cancer Medicine · doi:10.1002/cam4.1422 · Cited by 2
Luttwak, E., Gatt, M. E., Lebel, E., Lavi, N., Tadmor, T., Kreiniz, N., Benyamini, N., Horowitz, N. A., Geva, M., Suriu, C., et al. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.06.002 · Cited by 2
Sadowska‐Klasa, A., Abba, M. E., Gajkowska-Kulik, J., & Zaucha, J. M. (2022) · Acta Oncologica · doi:10.1080/0284186x.2022.2083921 · Cited by 2
Pandit, A., Wei, L., Bustamante, L., Elder, P., Falk, W., Sell, M. L., Rosko, A. E., Benson, D. M., Devine, S. M., Hofmeister, C. C., et al. (2019) · Archives of Hematology and Blood Diseases · doi:10.22259/2639-3581.0201003 · Cited by 2
Self-citationFirst-line treatment of multiple myeloma in both transplant and non-transplant candidates
Oriol, A., Abril, L., & Ibarra, G. (2023) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2023.2213891 · Cited by 2
Congressional Investigation of RevAssist-Linked and General Pricing Strategies for Lenalidomide
Bennett, C. L., Gibbons, J. B., Trujillo, A. J., Carson, K. R., Knopf, K., Nabhan, C., Rosen, S. T., & Aboulafia, D. M. (2024) · JCO Oncology Practice · doi:10.1200/op.23.00579 · Cited by 2
Hashiguchi, M., Okamura, T., Nomura, K., Nakamura, T., Kawaguchi, K., Koteda, S., Morishige, S., Oku, E., Takata, Y., Seki, R., et al. (2016) · Molecular and Clinical Oncology · doi:10.3892/mco.2016.747 · Cited by 2
Biran, N., Rowley, S. D., Vesole, D. H., Zhang, S., Donato, M. L., Skarbnik, A. P. Z., Richter, J. R., Pecora, A. L., & Siegel, D. S. D. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0534-0 · Cited by 2
Total Marrow Irradiation in Multiple Myeloma
Sahebi, F. (2020) · Springer eBooks · doi:10.1007/978-3-030-38692-4_10 · Cited by 2
Wahab, A., Rafae, A., Faisal, M. S., Mushtaq, K., Ehsan, H., Khakwani, M., Ashraf, A., Rehan, T., Ahmed, Z., Shah, Z., et al. (2020) · Expert Review of Hematology · doi:10.1080/17474086.2020.1839886 · Cited by 2
Kalff, A., Khong, T. T., Ramachandran, M., Walker, P., Schwarer, A. P., Roberts, A. W., Campbell, P. J., Filshie, R., Norton, S., Reynolds, J., et al. (2021) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.1080/10428194.2021.1948030 · Cited by 2
Lenalidomide maintenance in myeloma
Gozzetti, A., Defina, M., & Bocchia, M. (2012) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2012.100-c1 · Cited by 2
Multiple Myeloma: Advances Reported in 2013 Are Useful in the Clinic
Anderson, K. C. (2014) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2014.0195 · Cited by 2
Self-citationThe Future of Myeloma Therapy: One Size Does Not Fit All
Richardson, P. G. G. (2016) · Journal of Oncology Practice · doi:10.1200/jop.2016.011502 · Cited by 2
Self-citationHolstein, S. A., Suman, V. J., & McCarthy, P. L. (2019) · Leukemia · doi:10.1038/s41375-018-0359-7 · Cited by 2
Self-citationDhanasiri, S. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0749-0 · Cited by 2
Editorial: Proteomic and metabolic reprogramming in myeloma cells within the tumor microenvironment
Milan, E., & Gullà, A. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1264740 · Cited by 2
Tanguay, M., Roy, J., Su, J., Gul, E., Reece, D. E., Venner, C. P., White, D. J., Chu, M. P., Jimenez‐Zepada, V. H., Song, K., et al. (2024) · Cancer Medicine · doi:10.1002/cam4.70332 · Cited by 1
Alhejazi, A., Alhuraiji, A., Nourallah, A., Alshehri, A. A., Usman, B., ElGohary, G. M., Malhan, H. M., Motabi, I., Farsi, K. A., Alshuaibi, M., et al. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1547138 · Cited by 1
Metadata
- Authors
- McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., Moreb, J. S., Callander, N. S., Van Besien, K., Gentile, T., Isola, L., Maziarz, R. T., Gabriel, D. A., Bashey, A., Landau, H., Martin, T., Qazilbash, M. H., Levitan, D., McClune, B., Schlossman, R., Hars, V., Postiglione, J., Jiang, C., Bennett, E., Barry, S., Bressler, L., Kelly, M., Seiler, M., Rosenbaum, C., Hari, P., Pasquini, M. C., Horowitz, M. M., Shea, T. C., Devine, S. M., Anderson, K. C., & Linker, C.
- Affiliations
- Roswell Park Comprehensive Cancer Center (US)
- The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (US)
- Duke University (US)
- Memorial Sloan Kettering Cancer Center (US)
- Dana-Farber Cancer Institute (US)
- Abramson Cancer Center (US)
- University of Minnesota Medical Center (US)
- Washington University in St. Louis (US)
- University of Florida (US)
- University of Wisconsin–Madison (US)
- State University of New York (US)
- Mount Sinai Hospital (US)
- Oregon Health & Science University (US)
- University of North Carolina at Chapel Hill (US)
- BMT Group (United States) (US)
- University of California, San Francisco (US)
- The University of Texas MD Anderson Cancer Center (US)
- University of Chicago (US)
- University of Chicago Medical Center (US)
- Medical College of Wisconsin (US)
- ORCID
- McCarthy, Philip L.
- Owzar, Kouros
- Hofmeister, Craig C.
- Hassoun, Hani
- Richardson, Paul G.
- Giralt, Sergio
- Stadtmauer, Edward A.
- Weisdorf, Daniel J.
- Vij, Ravi
- Moreb, Jan S.
- Callander, Natalie Scott
- Gentile, Teresa
- Isola, Luis
- Maziarz, Richard T.
- Landau, Heather
- Martin, Thomas
- Qazilbash, Muzaffar H.
- McClune, Brian
- Jiang, Chen
- Bennett, Elizabeth
- Kelly, Michael
- Rosenbaum, Cara
- Hari, Parameswaran
- Pasquini, Marcelo C.
- Horowitz, Mary M.
- Devine, Steven M.
- Anderson, Kenneth C.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2012-05-10
- Volume
- 366
- Issue
- 19
- Pages
- 1770-1781
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- PMC
- PMC3744390
- OpenAlex
- W2125721471
- Semantic Scholar
- b20a8f57aae32a45c1804976b107b4ba1609688f
- Cited by
- 1,147
- References
- 42
- Citations by year
- 2026: 28 · 2025: 30 · 2024: 40 · 2023: 40 · 2022: 51 · 2021: 74 · 2020: 81 · 2019: 70 · 2018: 82 · 2017: 104 · 2016: 107 · 2015: 100 · 2014: 113 · 2013: 144 · 2012: 81
- FWCI
- 93.26
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons@Becker (Washington University School of Medicine) (submittedVersion)
- Funders
- National Heart, Lung, and Blood Institute (U10HL069334, U10HL069301, U10HL069348, U10HL109526, U01HL069294, U10HL069294, U10HL069330, U10HL069315, U10HL069290, U10HL069286, UG1HL069286, UG1HL069315)
- National Cancer Institute (U10CA033601, P50CA100707, U10CA031946, U10CA021115, U24CA076518)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Keywords
- lenalidomide, multiple myeloma, autologous stem cell transplantation, maintenance therapy, time to progression, overall survival, secondary malignancies, hematologic adverse events, drug toxicity
- MeSH terms
- Lenalidomide, Adult, Aged, Antineoplastic Agents, Double-Blind Method, Female, Follow-Up Studies, Humans, Male, Middle Aged, Multiple Myeloma, Thalidomide, Neoplasms, Second Primary, Disease-Free Survival, Stem Cell Transplantation, Maintenance Chemotherapy
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
